<DOC>
	<DOCNO>NCT00809328</DOCNO>
	<brief_summary>Azithromycin high rate clinical response eradication , wide spectrum activity , suppose development azithromycin injectable formulation Japan would deliver benefit patient community acquire pneumonia .</brief_summary>
	<brief_title>The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia ( CAP )</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<criteria>16 year age old patient CAP . Patients diagnose moderate severity . Known suspected hypersensitivity intolerance azithromycin , macrolides , ketolides . Hepatic dysfunction ( AST , ALT , total bilirubin &gt; 3 time institutional normal ) . Severe renal dysfunction ( creatinine clearance &lt; 30 ml/min ) . Patients history severe heart disease ( 4th degree NYHA ) . Patients congenital sporadic long QT syndrome , receive drug report QT prolongation . Severe underlying disease .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>